Milestone Scientific's Financial Update for 2024
Milestone Scientific Inc. (NYSE: MLSS), renowned for its innovative computerized drug delivery technologies, has shared an overview of its financial performance for the year ended December 31, 2024. The company has reported a revenue of approximately $8.6 million, reflecting a slight decline from the previous year's earnings of $9.8 million.
Neal Goldman, the Chairman and Interim Chief Executive Officer, expressed optimism about the future, emphasizing that 2024 was pivotal for laying the groundwork for growth. The company is focusing on streamlining its operations and enhancing profitability. Initial results from the first quarter of 2025 are promising, indicating potential growth across both the dental and medical sectors.
Significant Advancements in Medical Technology
Milestone Scientific has made remarkable strides in advancing its CompuFlo® Epidural System, signaling a significant opportunity for expanded market penetration. In 2024, the favorable Medicare Part B physician payment rates assigned to this technology by First Coast Service Options and Novitas Solutions in various jurisdictions now opens doors to a broader range of healthcare providers. This essential development will boost adoption rates, making quality pain management options more accessible.
One of Milestone's noteworthy achievements includes securing a contract for the Federal Supply Schedule (FSS), which allows federal facilities to procure the CompuFlo system. This will enhance how the technology is utilized in critical support scenarios, such as within the U.S. Department of Veterans Affairs and other federal healthcare services.
Robust Growth in Private Sector Adoption
Beyond federal collaborations, Milestone has observed considerable traction in the private healthcare sector. New service rollouts in 2025 at notable clinics such as Advanced Spine and Pain Management, Pain Doctors Medical LLC, and InfiniSurg demonstrate growing confidence in the CompuFlo technology. The partnership with Axial Biologics is further amplifying the company's distribution capabilities throughout essential U.S. markets.
In the dental healthcare arena, the STA Single Tooth Anesthesia System continues to lead globally in computer-controlled local anesthetic administration. Having delivered over 95 million injections, Milestone is also tapping into e-commerce to enhance direct sales and improve profit margins, a move that has been receiving positive feedback from users.
Financial Performance and Future Outlook
In reviewing its financial results, Milestone reported a decrease in both gross profit and operating loss for 2024, yet there were signs of operational improvements. The reduction in operational losses from $7.1 million in 2023 to $6.8 million in 2024 indicates a positive shift in operational efficiency.
The net loss narrowed from $6.9 million to approximately $4.7 million, marking an encouraging decline of nearly 32%. With cash reserves of $3.3 million and no outstanding debts, the company is strategically positioned to seize upcoming opportunities in the market.
Goldman concluded that the company stands on the verge of unlocking its full commercial potential, driven by positive clinical responses and strong e-commerce sales. The encouraging figures from Q1 2025 have increased their confidence in continued growth both in the medical and dental sectors.
Looking Towards 2025: Road Ahead for Milestone Scientific
With the upcoming year positioned as a critical phase for Milestone Scientific, the anticipation around continued advances in technology and growing market recognition is palpable. Their strategic focus on improving operational efficiencies and expanding the reach of their flagship products sets a hopeful trajectory as they head into 2025.
Frequently Asked Questions
What are the key financial results for Milestone Scientific in 2024?
Milestone Scientific reported approximately $8.6 million in revenue for the year 2024, down from $9.8 million in 2023, while also showing improvements in reducing operating losses.
How has the CompuFlo® Epidural System performed?
The CompuFlo® Epidural System has gained traction in several states as Medicare has assigned favorable payment rates, enhancing its adoption across healthcare facilities.
What recent developments occurred in Milestone's federal initiatives?
Milestone secured a contract for the Federal Supply Schedule, allowing federal medical facilities to purchase the CompuFlo®, increasing accessibility in essential healthcare programs.
What role does e-commerce play in Milestone's strategy?
The company has leveraged e-commerce for its STA System, which has greatly improved direct sales, engaging more customers while also enhancing profit margins.
What is Milestone's outlook for 2025?
With promising early performance in Q1 2025, the company is optimistic about achieving growth in both its dental and medical sectors, building on the improvements made in 2024.
